未知股票 CITE 深 沪
等待开盘 05-29 09:30:00 美东时间
0.00
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 总市值 0
- 52周最高 --
- 市盈率 静 0.00
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 799.94万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 0.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has...
2025-12-19 20:55
The Race for Resources: $4,300 Gold Triggers Aggressive Global Drilling Frenzy
Issued on behalf of GoldHaven Resources Corp. USANewsGroup.com News Commentary VANCOUVER, BC, Dec. 17, 2025 /PRNewswire/ -- For the second time this year, gold trading above $4,300 per ounce...
2025-12-18 00:55
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors ...
2025-12-17 02:17
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- The cell therapy manufacturing sector reached a pivotal inflection poi...
2025-12-17 00:53
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immu...
2025-12-12 23:47
AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 bi...
2025-12-12 22:49
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
2025-12-11 23:17
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 9, 2025 /PRNewswire/ -- Equity Insider News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrou...
2025-12-10 00:57
TWG Announces Pricing of $5.04 million Public Offering
Top Wealth Group Holding Limited (NASDAQ: TWG) announced the pricing of a best-efforts public offering of 720,000 units at $7.00 per Unit. Each Unit includes one Class A ordinary share, one Series A Class A Warrant, and one Series B Class A Warrant. The warrants have an exercise price of $7.00 and will expire in five years (Series A) and 18 months (Series B). The offering is expected to close on December 10, 2025. Gross proceeds are approximately...
2025-12-09 13:14
TWG Projects Strong Profit Growth for 2025
Top Wealth Group Holding Limited announced a positive profit outlook for its 2025 financial year, expecting net profits of at least $4 million, a significant rebound from a $2 million loss in the previous year. The improvement is attributed to enhanced business operations. The Company specializes in premium sturgeon caviar, with its "Imperial Cristal Caviar" brand achieving strong sales growth.
2025-12-05 21:00
